Posted by Michael Wonder on 15 Nov 2017
Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma
14 November 2017 - FDA approval based on Phase III programme demonstrating up to 51% reduction in asthma exacerbations, significant improvement in lung function and a 75% reduction in daily oral steroid use.
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US FDA has approved Fasenra (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
